Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs

Eli Lilly continues to rapidly capture the obesity and type 2 diabetes treatment markets, with its flagship tirzepatide sales reaching $8.58 billion in Q2 2025, a 98% year-on-year increase despite competition. The company further solidified its position in the GLP-1 drug market, estimated at $126 billion by 2029, with positive Phase 3 ATTAIN-2 study data for its oral experimental drug, orforglipron, which showed a 10.5% body weight reduction at week 72. This robust performance and pipeline strength have prompted an analyst upgrade of LLY stock from 'Hold' to 'Buy'.

Analysis

Eli Lilly (LLY) is demonstrating significant momentum in the rapidly expanding GLP-1 agonist market, which is projected to reach $126 billion by 2029. The company's flagship tirzepatide franchise posted remarkable sales of $8.58 billion in Q2 2025, a 98% year-over-year increase, underscoring its ability to capture market share despite strong competition from Novo Nordisk. This robust commercial performance is further bolstered by a promising pipeline, highlighted by positive Phase 3 data for its next-generation oral drug, orforglipron. The ATTAIN-2 study showed orforglipron achieved a 10.5% reduction in body weight at 72 weeks, substantially outperforming the 2.2% reduction in the placebo group. The potential for a convenient oral treatment strengthens LLY's long-term competitive positioning and supports the analyst's decision to upgrade the stock's rating from 'Hold' to 'Buy'.

Key Decisions for Investors

• Given the reported 98% year-over-year sales growth for tirzepatide and the analyst's upgrade to 'Buy', investors may consider the stock's bullish thesis to be well-supported by both current fundamentals and future growth prospects.
• Monitor the clinical and regulatory progress of the oral drug orforglipron, as its successful commercialization could significantly expand Eli Lilly's market access and solidify its leadership in the competitive obesity treatment landscape.
• Investors should assess whether the stock's current valuation fully prices in the high expectations for continued dominance in the GLP-1 market, considering the strong positive sentiment and rapid growth trajectory.